跳至主要内容
临床试验/JPRN-jRCTb050200131
JPRN-jRCTb050200131暂停3 期

Implement of Autologous Skeletal Myoblast Cell Sheet Transplantation for Dilated Cardio myopathy aiming Precision Medicine (Imple ment of Autologous Skeletal Myoblast Cell Sheet Transplantation for Dilated Cardiomyo pathy aiming Precision Medicine)

miyagawa shigeru0 个研究点目标入组 4 人开始时间: 2021年2月9日最近更新:
适应症

试验速览

阶段
3 期
状态
暂停
发起方
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 ot applicable(—)
性别
All

入选标准

  • 1)Diagnosed with dilated cardiomyopathy
  • 2)Participate in a series of studies including genetic analysis
  • 3)Suffering from heart failure of NYHA class III or IV
  • 4)Worsening heart failure despite receiving maximum medical therapy such as digitalis, diuretic, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, beta blocker, aldosterone antagonist, and oral inotropic agents
  • 5)16 years of age or older when at the time of informed consent
  • 6)Concerned worsening heart failure despite receiving the standard surgical treatment (left ventricular reconstruction, mitral valve procedure, and so on) and medical treatment over 3 months ago
  • 7)Left ventricular ejection fraction of <=35% in echocardiography at rest from the past 3 months before the informed consent to the enrollment
  • 8)Patients who can consent to participate in this regenerative therapy research in writing by themselves or patients and their guardians can inform consent if they are minor

排除标准

  • 1)Having symptoms of musculoskeletal disease
  • 2)Infected with HIV, HBV, HCV, or HTLV-1
  • 3)Cardiogenic shock due to worsening heart failure
  • 4)Having irreversible organ failure other than their hearts
  • 5)Having malignant tumor
  • 6)Pregnant or possibility of pregnant
  • 7)Refusal of transfusion
  • 8)Having past history of drug or alcohol addiction in the past 6 months before the informed consent
  • 9)Allergy of antibiotics or raw material of animal origin such as fetal bovine serum
  • 10)Having severe pulmonary hypertension
  • 11)Participation in another clinical trial(except for the programing device) or intervention in the past 6 months
  • 12)Patients judged inappropriate to participate in this regenerative therapy with any reasons by the principal investigator or subinvestigators

研究者

发起方
miyagawa shigeru

相似试验

进行中(未招募)
1 期
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients.MedDRA version: 17.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856
EUCTR2010-021463-32-SIInnovacell Biotechnologie AG252
进行中(未招募)
1 期
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.
EUCTR2010-021463-32-ATInnovacell Biotechnologie AG252
进行中(未招募)
1 期
A clinical trial comparing muscle cell treatment with placebo in fecal incontinence patientsFecal incontinence
EUCTR2021-001376-42-BGInnovacell AG290
进行中(未招募)
1 期
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients.MedDRA version: 17.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000004856
EUCTR2010-021463-32-CZInnovacell Biotechnologie AG252
招募中
1 期
A clinical trial treating fecal incontinence patients with muscle cell treatment
EUCTR2021-005399-21-ATInnovacell AG10